News

Prima-Temp Announces New Leadership, Investment, and CE Mark Certification

Wednesday, May 08, 2019

BOULDER, Colo., May 3, 2019 /PRNewswire/ -- Boulder, Colorado based Prima-Temp, Inc. a developer and manufacturer of AI-assisted fertility management products, announced today that in March, it raised $5M in new funding from the Hungarian pharmaceutical company Gedeon Richter, and in April achieved CE mark certification for its Priya Fertility Sensor product. 

Weekly Policy Update: The Final Tally - 2019 Legislative Session Comes to a Close

Friday, May 03, 2019

CBSA has worked hard this session to advocate on behalf of the industry. We’ve worked with our members and partners to advance proposals that promote patient safety, protect patient access, and enhance workforce development efforts, while coordinating to convey concerns with problematic legislation and mitigate threats to the industry in Colorado. 

Weekly Policy Update: One Week Left - What Will Make It Across the Finish Line

Friday, April 26, 2019

  

CBSA Opposes Drug Importation and Continues to Advocate for Safe Policy to Reduce Patient Costs

Monday, April 22, 2019

Last week CBSA testified in the House Health and Insurance Committee in opposition to Senate Bill 005 - Import Prescription Drugs From Canada, which would require the Department of Health Care Policy and Financing to design a program to import prescription drugs from Canada for sale to Colorado consumers. CBSA expressed our concerns that opening up the U.S. supply chain would jeopardize safety by exposing patients to counterfeit, adulterated or unapproved drugs and would result in minimal savings for consumers. In fact, both the Department of Health and Human Services and the Congressional Budget Office have stated that savings from importation would be minimal; estimates suggest less than one percent.  

Weekly Policy Update: CBSA Applauds Introduction of House Bill to Permanently Repeal Medical Device Excise Tax

Friday, April 12, 2019

This week bipartisan legislation was introduced in the U.S. House of Representatives to permanently repeal the medical device excise tax. CBSA applauds the introduction of H.R. 2207, Protect Medical Innovation Act of 2019, which gets us one step closer to providing innovators the long-term certainty they need to support future job growth and sustainable, cutting-edge research and development.  

AdvaMed President and CEO Releases Statement On the House Bill To Repeal the Medical Device Tax

Thursday, April 11, 2019

WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued the following statement on introduction of bipartisan legislation (H.R. 2207) in the U.S. House of Representatives to permanently repeal the medical device excise tax:

“America’s medical technology industry is facing a $20 billion tax increase at year-end, when the current medical device tax suspension expires. Urgent action is essential to protect future medtech innovations that benefit patients and to avoid putting good-paying U.S. jobs at risk.

“House introduction today of the ‘Protect Medical Innovation Act of 2019’ in the 116th Congress brings us one step closer to ensuring this innovation-stifling burden on the medtech industry never returns, supporting continued American leadership of this vital industry.

“We thank the bill’s lead sponsors, Reps. Ron Kind (D-Wis.), Jackie Walorski (R-Ind.), Scott Peters (D-Calif.), and Richard Hudson (R-N.C.) for their leadership on this issue. This bill – and the strong bipartisan support they have gathered – reflect the high priority this Congress places on patients, jobs, and future investment.

“While past suspensions of the medical device tax have enabled manufacturers to invest in R&D, infrastructure and new hiring – which in turn benefits patients and the U.S. economy – these benefits are at risk. Now that bipartisan legislation to permanently repeal the device tax has been introduced in both the House and Senate, AdvaMed will urge Congress and the administration to act as expeditiously as possible to get rid of the tax once and for all this year.”

 
Continue Reading

Inscripta Completes $20M Expansion of Series C Financing, Increasing Total Round to $105.5M

Monday, April 08, 2019

Inscripta, a leading gene editing technology company, today announced that it has increased its previously announced Series C financing with an additional $20 million from existing investors. The new funding adds to the $85.5 million financing Inscripta announced in 2018, bringing the total raised for the round to $105.5 million. 

Weekly Policy Update: Drug Pricing Transparency Bill Introduced in Colorado, Plus CBSA Advocates in DC

Friday, April 05, 2019

 

CBSA and BIO Honor Colorado Congressional Leaders as Innovators in Biotechnology

Thursday, April 04, 2019

Senator Michael Bennet, Congresswoman Diana DeGette Recognized as Champions of Life Science 
Continue Reading

Colorado BioScience Association Applauds Expansion by Novartis Company AveXis to Longmont

Monday, April 01, 2019

April 1, 2019